ALS: focus on purinergic signalling

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease characterized by progressive paralysis and neuroinflammation.
• The multi-factorial nature of ALS presents challenges in identifying unique mechanisms and effective treatments.
• Extracellular purines and pyrimidines are critical signaling molecules involved in neurotransmission, muscle function, and immune responses.

Purpose of the Study:

• To review the early cellular and molecular interactions of purinergic pathways in ALS pathogenesis.
• To investigate the role of purinergic signaling in the neuroinflammatory cascade of ALS.
• To highlight the potential of purinergic dynamics as therapeutic targets for ALS.

Main Methods:

• Literature review focusing on purinergic signaling in neurodegenerative and neuroinflammatory diseases, specifically ALS.
• Analysis of studies investigating purinergic receptors (P1, P2) and nucleotide transporters in ALS.
• Synthesis of current knowledge on extracellular purine/pyrimidine involvement in ALS etiopathology.

Main Results:

• Purinergic pathways, including P1 and P2 receptors and nucleotide transporters, are modulated in ALS cells and tissues.
• Extracellular purines and pyrimidines act as crucial neuron-to-glia alarm signals in the nervous system.
• These molecules play a significant role in the neuroinflammatory processes that accelerate ALS progression.

Conclusions:

• Understanding purinergic signaling in ALS offers novel research perspectives and disease modeling approaches.
• Targeting purinergic pathways may lead to the development of more effective therapeutics for ALS.
• Further research into purinergic dynamics is essential for combating this progressive neurodegenerative disorder.